Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X

Abreu-González, Pedro; Avanzas, Pablo; Gómez, María Ángeles; Kaski, Juan Carlos

doi:10.1016/j.atherosclerosis.2010.09.031

Cited by 12 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In accordance with those findings, data from Lanza GA, et al also demonstrated an increased level of interleukin-1 (IL-1) receptor antagonist in patients with cardiac syndrome X, unrelated with infectious burden [23]. More recent data showed that soluble CD40 ligand (sCD40L) was associated with ischemic burden in patients with cardiac syndrome X, suggesting the potential role of this inflammatory molecule in the pathogenesis of cardiac syndrome X deserves further investigation [24].…”

Section: Discussionsupporting

confidence: 68%

“…One of the most possible mechanisms may be related to inflammation. In fact, emerging findings have suggested a role of inflammation in coronary endothelial dysfunction in cardiac syndrome X [19,[22][23][24][25][26][27]. Tousoulis et al, found that serum levels of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) were significantly higher in patients with cardiac syndrome X. Pathophysiologically, those adhesion molecules are usually synthesized by activated endothelial cells in response to inflammatory stimuli [22].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Red Blood Cell Distribution Width in Patients with Cardiac Syndrome X

et al. 2013

View full text Add to dashboard Cite

Abstract. BACKGROUND: Cardiac syndrome X (CSX) is a condition characterized by chest pain with normal coronary arteries. However, its pathogenesis has not fully been understood yet. Red blood cell distribution width (RDW) has recently been suggested as a marker of acute and chronic cardiovascular diseases, while no data is available in patients with CSX. METHODS: One hundred and twenty consecutive patients with CSX and 102 normal controls were prospectively enrolled in this study. Blood samples were drawn from all individuals for measuring RDW and high-sensitivity C-reactive protein (CRP). The baseline data were compared between patients with CSX and normal controls. RESULTS: The RDW levels were significantly higher in patients with CSX than that in those with normal controls (13.1 ± 2.1 versus 12.3 ± 1.8, p = 0.011). Moreover, the data showed that the levels of plasma CRP were marked higher in patients with CSX than those that were observed in normal controls (CRP: 2.8 ± 2.2 mg/L versus 2.0 ± 1.7 mg/dl, p = 0.014). In addition, the multivariate analysis indicated that peripheral monocyte cell, CRP and RDW were the independent variables most strongly associated with CSX. In a receiver operating characteristic (ROC) curve analysis, we found that an RDW value of 12.8% was used as an effective cut-point in the segregation of the presence or absence of cardiac syndrome X, a sensitivity of 52.0% and a specificity of 65.4% were obtained. Finally, correlation analysis suggested that there was positive correlation between plasma levels of CRP and RDW levels (n = 120, γ = 0.381, P = 0.013). CONCLUSIONS: The present study, for the first time, demonstrated that elevated RDW and CRP levels were independently associated with the presence of CSX.

show abstract

Section: Discussionsupporting

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Evaluation of Red Blood Cell Distribution Width in Patients with Cardiac Syndrome X

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The CD40 ligand (CD40L) is a new inflammatory transmembrane protein that belongs to the tumor necrosis family. CD40L and its soluble form (sCD40L) are expressed in a variety of cell types, including activated T‐cells, and may serve as a link between inflammation and atherosclerosis . Studies have demonstrated that raised circulating levels of sCD40L have been associated with an increased risk of cardiovascular risk factors and cardiovascular events .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of serum sCD40L and homocysteine levels with subclinical atherosclerosis indicators in patients with psoriasis: a pilot study

et al. 2014

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory process associated with an increased risk of cardiovascular risk factors. sCD40L has been suggested to have a possible role in the pathogenesis, of psoriasis and is known to be associated with inflammation, atherogenesis and cardiovascular events. This study investigated cardiovascular risk factors (sCD40L and homocysteine) as well as subclinical atherosclerosis indicators in psoriatic patients and control subjects. The study included 56 consecutive patients with chronic plaque-type psoriasis and 53 age and gender matched healthy controls admitted to a university hospital. Serum sCD40L and homocysteine levels were measured by ELISA. Carotid artery intima-media thickness and brachial artery flow mediated dilatation (FMD) measurements were determined ultrasonographically. Subjects who had a history of cardiovascular diseases and cardiovascular risk factors and receiving any systemic treatment were excluded from the study. Plasma sCD40L levels were significantly higher in psoriasis patients compared with healthy controls (1.33±0.72 vs. 0.98±0.70 ng/ml P=0.012), whereas plasma homocysteine levels did not differ significantly between the two groups. FMD was significantly reduced in the psoriasis group compared to the controls (3.83±5.03 vs. 8.45±7.27% P=0.0001). Multiple linear regression analyses indicated a significant association between psoriasis, sCD40L, and FMD. Psoriatic patients had higher sCD40L levels than healthy controls, which may lead to an increase in cardiovascular diseases. sCD40L may be a more reliable and early predictive marker of cardiovascular events in psoriatic patients. New treatmentoptions that will be developed over sCD40L will benefit in prevention of psoriasis and its cardiovascular comorbidities.

show abstract

“…The CD40/CD40 ligand system has a widely accepted role in atherothrombosis (31). Elevated levels of soluble CD40 have already been shown to be associated with severe ischemic burden in cardiac syndrome X (32). In view of the prognostic role of slow flow in cardiac syndrome X and the evidence that elevated soluble serum CD40 can be a predictor of ischemia magnitude, the results of the study published in the present issue of the Anatolian Journal of Cardiology appear particularly stimulating (21).…”

mentioning

confidence: 62%

The light of inflammation in the darkness of the coronary slow flow phenomenon

Fragasso¹,

Maranta²

2012

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X

Cited by 12 publications

References 33 publications

Evaluation of Red Blood Cell Distribution Width in Patients with Cardiac Syndrome X

Evaluation of Red Blood Cell Distribution Width in Patients with Cardiac Syndrome X

Evaluation of serum sCD40L and homocysteine levels with subclinical atherosclerosis indicators in patients with psoriasis: a pilot study

The light of inflammation in the darkness of the coronary slow flow phenomenon

Contact Info

Product

Resources

About